Cipher Pharmaceuticals Inc  

(Public, TSE:DND)   Watch this stock  
Find more results for DND
+0.07 (0.45%)
Nov 21 - Close
TSE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 15.40 - 15.90
52 week 6.76 - 16.28
Open 15.90
Vol / Avg. 74,749.00/145,526.00
Mkt cap 398.13M
P/E 12.54
Div/yield     -
EPS 1.24
Shares 25.64M
Beta -1.70
Inst. own     -
Sep 9, 2014
Cipher Pharmaceuticals Inc at Rodman & Renshaw Global Investment Conference

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin 120.04% 92.43%
Operating margin 62.40% 67.22%
EBITD margin - 71.39%
Return on average assets 53.43% 64.43%
Return on average equity 64.75% 97.60%
Employees 13 -
CDP Score - -


409 Matheson Blvd E
+1-905-6025840 (Phone)
+1-905-6020628 (Fax)

Website links


Cipher Pharmaceuticals Inc. is a specialty pharmaceutical company. The Company has three commercial products and a fourth in development, which are improved formulations of marketed drugs. The Company acquires products that fulfill unmet medical needs, manage the required clinical development and regulatory approval process, and market those products either directly or through partners. Its core capabilities include clinical and regulatory affairs, product licensing, supply chain management, and marketing and sales. The Company has regulatory marketing approval in the United States and Canada for all three of its original products and has completed eight marketing partnerships.

Officers and directors

Gerald P. McDole Independent Chairman of the Board
Age: 74
Larry Andrews President, Director, IR Contact Officer
Shawn Patrick O'Brien Chief Executive Officer
Norman C. Evans Chief Financial Officer, Secretary
Joan Chypyha Vice President - Marketing and Sales, Director of Sales, Director of Marketing
Jason A. Gross Pharm.D. Vice President - Scientific Affairs
Stefan Aigner M.D. Independent Director
William D. Claypool M.D. Independent Director
Age: 61
John D. Mull M.D. Independent Director
Thomas G. Wellner Independent Director